- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of October 16
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of October 16.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 16.
Number 5: Insurer Anthem has announced that it is parting ways with Express Scripts in order to found its own pharmacy benefit management company, IngenioRx.
Number 4: The Senate Health, Education, Labor and Pensions Committee heard testimony from pharmaceutical manufactures and the supply chain in a full committee hearing on Tuesday, facing pointed questions about drug rebates.
Number 3: Switching patients from originator biologics to biosimilars has been shown to have an association with the so-called “nocebo” effect, in which negative expectations lead to worse outcomes.
Number 2: Dr Angus Worthing, practicing rheumatologist and chair of the American College of Rheumatology's Government Affairs Committee, spoke to The Center for Biosimilars® about the need for Congress to adequately fund the FDA and to provide adequate budget for healthcare.
Number 1: Contributor Amanda Forys of Xcenda explains the challenges that lie ahead for the biosimilars market.
Finally, last week, our newsletter asked for your thoughts on whether transfers of drug patents to sovereign entities should be permitted under US law. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
